. Author manuscript; available in PMC: 2019 Nov 1.

Published in final edited form as: Pharmacoepidemiol Drug Saf. 2018 Sep 24;27(11):1209–1216. doi: 10.1002/pds.4657

Table 1 –

Baseline Characteristics

Baseline Characteristics		All (n=2,547)		Non-tenofovir users (n=1,844)		Tenofovir users (n=703)
Age (years)	Median (IQR)	35.6	(30.5, 42.3)	35.7	(30.6, 42.3)	35.4	(30.4, 42.0)
Sex	Male	1,796	70.5%	1,302	70.6%	494	70.3%
Height (cm)	Median (IQR)	165	(158, 171)	165	(158, 170)	166	(159, 171)
Height (cm)	n	2,348	91.2%	1,696	92.0%	652	92.7%
Weight (kg)	Median (IQR)	56.0	(49.0, 64.7)	56.0	(48.5, 63.7)	57.5	(50.2, 66.5)
Weight (kg)	n	2,224	86.4%	1,603	86.9%	621	88.3%
eGFR (ml/min/1.73m²)	Median (IQR)	104.1	(89.0, 115.4)	103.3	(88.2, 115.2)	106.6	(91.9, 116.0)
HIV exposure	Heterosexual	1,533	60.2%	1,128	61.2%	405	57.6%
	Homosexual	635	24.9%	419	22.7%	216	30.7%
	IDU	148	5.8%	109	5.9%	39	5.6%
	Other	231	9.1%	188	10.2%	43	6.1%
Hypertension	Yes	113	4.4%	76	4.1%	37	5.3%
Diabetes	Yes	51	2.0%	43	2.3%	8	1.1%
Hepatitis B surface antigen status	Negative, % tested	2,098	90.3%	1,571	92.0%	527	85.6%
	Positive, % tested	225	9.7%	136	8.0%	89	14.4%
	Unknown	224	8.8%	137	7.4%	87	12.4%
Hepatitis C antibody status	Negative, % tested	1,865	86.8%	1,404	86.1%	461	89.0%
	Positive, % tested	284	13.2%	227	13.9%	57	11.0%
	Unknown	398	15.6%	213	11.6%	185	26.3%
CDC category	1	1,283	50.4%	860	46.6%	423	60.2%
	2	415	16.3%	310	16.8%	105	14.9%
	3	849	33.3%	674	36.6%	175	24.9%
Nadir CD4 cell count (cells/mm³)	Median (IQR)	139	(46, 228)	122	(38, 210)	183	(79, 276)
Nadir CD4 cell count (cells/mm³)	n	2,515	97.7%	1,818	98.6%	697	99.1%
HIV viral load (log₁₀ copies/mL)	Median (IQR)	4.9	(4.3, 5.4)	4.9	(4.3, 5.4)	4.9	(4.3, 5.3)
HIV viral load (log₁₀ copies/mL)	n	1,609	62.5%	1,043	56.6%	566	80.5%
Protease inhibitor use	Yes	475	18.7%	269	14.6%	206	29.3%

Values are n (%total) unless otherwise indicated. eGFR, estimated glomerular filtration rate; CDC, Centers for Disease Control and Prevention; IQR, interquartile range; IDU, intravenous drug use